Results 51 to 60 of about 5,710 (181)

Monotherapy with the PCSK9 inhibitor alirocumab versus ezetimibe in patients with hypercholesterolemia:Results of a 24week, double-blind, randomized Phase 3 trial [PDF]

, 2014
Background:Efficacy and safety of alirocumab were compared with ezetimibe in hypercholesterolemic patients at moderate cardiovascular risk not receiving statins or other lipid-lowering therapy. Methods In a Phase 3, randomized, double-blind, double-dummy
Merlet, Laurence, Robinson, Jennifer G., Kastelein, John J.P., Roth, Eli M., Colhoun, Helen M., Pordy, Robert, Taskinen, Marja-Riitta, Ginsberg, Henry N., Kastelein, John J. P., Baccara-Dinet, Marie T.   +9 more
core   +1 more source

Hypocholesterolemia in liver and cardiovascular disease: Friend or foe?

Journal of Internal Medicine, EarlyView.
Abstract Hypocholesterolemia is perceived as benign given its association with lower cardiovascular risk. However, genetic and epidemiological evidence indicates that persistently low levels of low‐density lipoprotein cholesterol (LDL‐C) and apolipoprotein B (ApoB) arise from distinct biological mechanisms with different hepatic implications ...
Valentina Flagiello, Emelie Barreby, Umberto Vespasiani‐Gentilucci, Stefano Romeo   +3 more
wiley   +1 more source

Leptin–cholesterol crosstalk in pregnancy: Mechanistic implications for placental function and cardiometabolic programming

Experimental Physiology, EarlyView.
Abstract Pregnancy requires the coordinated maternal reorganization of lipid and endocrine pathways to sustain fetal growth and anticipate neonatal nutrition. Leptin, produced by adipose tissue and the placenta, acts as an integrative signal linking maternal energy status with trophoblast function and vascular adaptation, while cholesterol provides ...
Julio Flores, Diego Gumera, Andreina Arias, Cristián A. Amador, María José Yañez   +4 more
wiley   +1 more source

Mechanical Thrombus Aspiration for a Young STEMI Patient With Plaque Erosion: Time for a Stent‐Free Approach?

Catheterization and Cardiovascular Interventions, Volume 108, Issue 3, Page 833-839, September 1, 2026.
ABSTRACT A 34‐year‐old man with no cardiovascular history presented with anterior ST‐elevation myocardial infarction and a large thrombotic occlusion of the mid left anterior descending artery. Following potent antithrombotic therapy and mechanical thrombus aspiration, angiography revealed vessel patency without residual significant stenosis, allowing ...
Domenico Simone Castiello, Francesco Greco, Antonio Curcio, Alberto Polimeni   +3 more
wiley   +1 more source

Evolocumab enables rapid LDL-C reduction and inflammatory modulation during in-hospital stage of acute coronary syndrome: A pilot study on Chinese patients

Frontiers in Cardiovascular Medicine, 2022
Background and aimsProprotein convertase subtilisin/kexin type 9 (PCSK9) has long been considered a key regulator in lipid metabolism. Its role as a potential player in immune response has recently earned much attention.
Ziwei Ou, Ziwei Ou, Zaixin Yu, Benhui Liang, Lin Zhao, Jianghua Li, Xinli Pang, Qiyun Liu, Cong Xu, Shaohong Dong, Xin Sun, Tangzhiming Li   +11 more
doaj   +1 more source

Myocardial Lipid Metabolism Imbalance: The Pathological Core and Novel Diagnostic‐Therapeutic Directions of Cardiovascular Diseases

Journal of Biochemical and Molecular Toxicology, Volume 40, Issue 8, August 2026.
In cardiac cells, Plin5/AMPK regulate lipid homeostasis; excess CD36‐mediated uptake drives lipotoxicity, mitochondrial dysfunction, and CVDs (e.g., heart failure). Biomarkers (ApoB/ApoA‐1) and therapies (SGLT2 inhibitors) target this cascade. ABSTRACT Cardiac lipid metabolism is fundamental to myocardial energy homeostasis, with fatty acid oxidation ...
Peiyun Xie, Qun Zeng, Hongrui Wang, Meihua She   +3 more
wiley   +1 more source

Effect of Evolocumab on Coronary Plaque Composition

, 2018
Background: Incremental low-density lipoprotein (LDL) cholesterol lowering with the proprotein convertase subtilisin kexin type 9 inhibitor evolocumab regresses coronary atherosclerosis in statin-treated patients.
Nissen, Steven E., Nicholls, Stephen J., Cho, Leslie, Brennan, Danielle M., Anderson, Todd, Ballantyne, Christie M., Wolski, Kathy, Scherer, Daniel J., Koenig, Wolfgang, Honda, Satoshi, Kassahun, Helina, Puri, Rishi, Yang, Jingyuan, Borgman, Marilyn, Wasserman, Scott M., Shishikura, Daisuke, Somaratne, Ransi, Kastelein, John J. P.   +17 more
core   +1 more source

Is there enough evidence with evolocumab and alirocumab (antibodies to proprotein convertase substilisin-kexin type, PCSK9) on cardiovascular outcomes to use them widely? [PDF]

, 2015
Introduction: Statins alone often do not reduce LDL cholesterol levels sufficiently to given maximum cardiovascular benefit. Thus, additional drugs are required to reduce the levels of LDL cholesterol.
Doggrell, Sheila Anne, Lynch, Kaileen Anne   +1 more
core   +1 more source

Lack of Differences in the Pharmacokinetics of Therapeutic Monoclonal Antibodies Between Japanese and Non‐Japanese Individuals

The Journal of Clinical Pharmacology, Volume 66, Issue 8, August 2026.
Abstract Evaluation of the pharmacokinetics (PK) of new drugs in Japanese individuals is regularly requested by the Japanese regulatory agency prior to participation in global clinical trials or for bridging approaches for regulatory approval. However, the need for PK assessments in the Japanese population may be less compelling for monoclonal ...
Paridhi Gupta, Ashish Sharma, Bernd Meibohm   +2 more
wiley   +1 more source

Evolocumab attenuate pericoronary adipose tissue density via reduction of lipoprotein(a) in type 2 diabetes mellitus: a serial follow-up CCTA study

Cardiovascular Diabetology, 2023
Background Pericoronary adipose tissue (PCAT) density is a biomarker of vessel inflammation, which is supposed to be increased in patients with type 2 diabetes mellitus (T2DM). However, whether the coronary inflammation revealed by this novel index could
Meng-Meng Yu, Xin Zhao, Yin-Yin Chen, Xin-Wei Tao, Jun-Bo Ge, Hang Jin, Meng-Su Zeng   +6 more
doaj   +1 more source